MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2010 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M-89.7% YoY

Gross Profit

$00.0% margin

Operating Income

-$37M-249.3% margin

Net Income

-$37M-253.1% margin

EPS (Diluted)

$-32.49

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$54M

Total Liabilities

$31M

Stockholders' Equity

$23M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$144M	-89.7%
Gross Profit	$0	$0	—
Operating Income	-$37M	$81M	-145.8%
Net Income	-$37M	$79M	-147.4%

MDGL FY 2010 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena